Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Dummer

Showing results (501-510 of 744) with videos related to

Pageof 75
Sort By:
Cell Reports|May 24, 2016
A Transcriptionally Inactive ATF2 Variant Drives MelanomagenesisGiuseppina Claps, Yann Cheli, Tongwu Zhang, et al.
Critical Reviews in Oncology/Hematology|July 13, 2023
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitorsPaolo Bossi, Paolo A Ascierto, Nicole Basset-Seguin, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 8, 2010
Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomasReinhard Dummer, Stefan Eichmüller, Sylke Gellrich, et al.
Plos One|October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
Journal of Crohn'S & Colitis|August 22, 2015
European Evidence-based Consensus: Inflammatory Bowel Disease and MalignanciesVito Annese, Laurent Beaugerie, Laurence Egan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Scientific Reports|July 19, 2016
Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophagesRoman Huber, Barbara Meier, Atsushi Otsuka, et al.
Pageof 75

Showing results (501-510 of 744) with videos related to

Sort By:
Pageof 75
Cell Reports|May 24, 2016
A Transcriptionally Inactive ATF2 Variant Drives MelanomagenesisGiuseppina Claps, Yann Cheli, Tongwu Zhang, et al.
Critical Reviews in Oncology/Hematology|July 13, 2023
Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitorsPaolo Bossi, Paolo A Ascierto, Nicole Basset-Seguin, et al.
JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.
The Lancet. Oncology|February 19, 2013
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 studyPaolo A Ascierto, Dirk Schadendorf, Carola Berking, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibitionLisa Zimmer, Uwe Hillen, Elisabeth Livingstone, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 8, 2010
Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomasReinhard Dummer, Stefan Eichmüller, Sylke Gellrich, et al.
Plos One|October 2, 2015
Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Joanna Mangana, Phil F Cheng, Katja Schindler, et al.
Journal of Crohn'S & Colitis|August 22, 2015
European Evidence-based Consensus: Inflammatory Bowel Disease and MalignanciesVito Annese, Laurent Beaugerie, Laurence Egan, et al.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2017
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage IIIJean Jacques Grob, Dirk Schadendorf, Paul Lorigan, et al.
Scientific Reports|July 19, 2016
Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophagesRoman Huber, Barbara Meier, Atsushi Otsuka, et al.
Pageof 75